cgp 48664 profile

4-amidinoindan-1-one 2'-amidinohydrazone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	9576789
CHEMBL ID	1202793
CHEMBL ID	65789
SCHEMBL ID	19379381
MeSH ID	M0219593

Synonym
sardomozide chloride
CHEMBL1202793 ,
4-amidinoindan-1-one-2'-amidinohydrazone
4-aiah
hydrazinecarboximidamide, 2-(4-(aminoiminomethyl)-2,3-dihydro-1h-inden-1-ylidene)-
cgp 48664
sam 486a
sam486a
(1e)-1-(carbamimidoylhydrazono)indane-4-carboxamidine
cgp-48664
cgp-48664a
urea azine with 1-oxo-4-indancarboxamidine
4-amidinoindan-1-one 2'-amidinohydrazone
CHEMBL65789
AKOS016004846
AKOS016000728
bdbm50368644
unii-ceb05s0b9i
ceb05s0b9i ,
sardomozide [inn]
4-(aminoiminomethyl)-2,3-dihydro-1h-inden-1-one-diaminomethylenehydrazone
(e)-2-(4-carbamimidoyl-2,3-dihydro-1h-inden-1-ylidene)hydrazinecarboximidamide
(e)-1-((diaminomethylene)hydrazono)-2,3-dihydro-1h-indene-4-carboximidamide
(2e)-2-(4-carbamimidoyl-2,3-dihydro-1h-inden-1-ylidene)hydrazinecarboximidamide
SCHEMBL19379381
HY-13746
CS-0007772
(1e)-1-(diaminomethylidenehydrazinylidene)-2,3-dihydroindene-4-carboximidamide
4-amidinoindan-1-one 2/'-amidinohydrazone
A926062
AKOS040737423

Excerpt	Reference	Relevance
" SAM486A plasma concentrations were measured during the first cycle for pharmacokinetic and pharmacodynamic evaluations."	( A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. Barbet, NC; Capdeville, R; Choi, L; Clark, GM; Eckhardt, SG; Gan, G; Hammond, LA; Hidalgo, M; Linnartz, R; Moczygemba, J; Porter, CW; Rowinsky, EK; Siu, LL; Sklenar, IT; Von Hoff, DD; Weiss, GR, 2002)	0.31
" Pharmacokinetic analyses demonstrated a rapid initial decrease in plasma drug concentrations at the end of infusion, followed by a long terminal elimination phase with a mean (+/- SD) terminal elimination half-life of 65."	( A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. Barbet, NC; Capdeville, R; Choi, L; Clark, GM; Eckhardt, SG; Gan, G; Hammond, LA; Hidalgo, M; Linnartz, R; Moczygemba, J; Porter, CW; Rowinsky, EK; Siu, LL; Sklenar, IT; Von Hoff, DD; Weiss, GR, 2002)	0.31
" Pharmacodynamic assessment of tumoral tissues in 1 study patient demonstrated changes in the levels of polyamines and their biosynthetic enzymes consistent with SAMDC inhibition."	( A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. Barbet, NC; Capdeville, R; Choi, L; Clark, GM; Eckhardt, SG; Gan, G; Hammond, LA; Hidalgo, M; Linnartz, R; Moczygemba, J; Porter, CW; Rowinsky, EK; Siu, LL; Sklenar, IT; Von Hoff, DD; Weiss, GR, 2002)	0.31

Excerpt	Reference	Relevance
"The purpose of our study was to determine the maximum-tolerated dose, dose-limiting toxicity, safety profile, and pharmacokinetics of the polyamine synthesis inhibitor SAM486A given in combination with 5-fluorouracil/leucovorin (5-FU/LV) in cancer patients."	( Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004)	0.32
"The novel molecular agent SAM486A is tolerable and safe in combination with a standard 5-FU regimen in patients with advanced colorectal cancer."	( Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004)	0.32
" However, drug combination therapies expected to potentiate the effects of these drugs have yet to be systematically pursued."	( The role of polyamines in human cancer: prospects for drug combination therapies. Bachmann, AS, 2004)	0.32

Excerpt	Relevance	Reference
" Although the three sublines were 2- to 10-fold less sensitive than the parent line to classical MDR-type agents, they were found in dose-response studies to be significantly more sensitive to DENSPM than the parent line."	( Collateral sensitivity of human melanoma multidrug-resistant variants to the polyamine analogue, N1,N11-diethylnorspermine. Bergeron, RJ; Ganis, B; Kramer, DL; Porter, CW; Rustum, Y; Wrzosek, C, 1994)	0.29
" A dosing regimen of four weekly infusions followed by 2 weeks off therapy was studied."	( Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group. Barbet, NC; Bruntsch, U; Capdeville, R; Choi, L; Denis, LJ; Eskens, FA; Greim, GA; Hanauske, AR; Muskiet, FA; Planting, AS; van Zuylen, C; Verweij, J; Wanders, J; Wolff, I, 2000)	0.31
" Treatment of cells with a second inhibitor of polyamine biosynthesis, the S-adenosylmethionine decarboxylase (SAMDC) inhibitor SAM486A, also resulted in a dosage dependent decrease in meprin alpha and MMP-7 mRNA."	( Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells. Bond, JS; Manni, A; Matters, GL, 2005)	0.33

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	27 (52.94)	18.2507
2000's	22 (43.14)	29.6817
2010's	1 (1.96)	24.3611
2020's	1 (1.96)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	7 (13.46%)	5.53%
Reviews	1 (1.92%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	44 (84.62%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
n'-acetylspermine N(1)-acetylspermine : An acetylspermine carrying an acetyl group at position N(1).	2.4	2	0	acetamides; acetylspermine	human metabolite
putrescine [no description available]	4.21	5	0	alkane-alpha,omega-diamine	antioxidant; fundamental metabolite
spermidine [no description available]	4.71	9	0	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
spermine [no description available]	4.2	17	0	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
pimagedine pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure. aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.	1.99	1	0	guanidines; one-carbon compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor; EC 1.4.3.4 (monoamine oxidase) inhibitor
camostat camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.	1.99	1	0	benzoate ester; carboxylic ester; diester; guanidines; tertiary carboxamide	anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor
eflornithine Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.	5.18	15	0	alpha-amino acid; fluoroamino acid	trypanocidal drug
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	4.36	2	2	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
gabexate Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.	1.99	1	0	benzoate ester
n(1),n(11)-diethylnorspermine N(1),N(11)-diethylnorspermine: structure given in first source	3.39	7	0
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.02	1	0	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.41	2	0	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.	2.04	1	0	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
fluorescein-5-isothiocyanate Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.	2	1	0	fluorescein isothiocyanate
etoposide [no description available]	2.4	2	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
1-aminooxy-3-aminopropane 1-aminooxy-3-aminopropane: polyamine biosyn inhibitor; structure given in first source	2.02	1	0
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	4.36	2	2	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
actinonin actinonin: natural hydroxamic acid, pseudopeptide antibiotic isolated from Streptomyces species; structure	2.02	1	0
aphidicolin Aphidicolin: An antiviral antibiotic produced by Cephalosporium aphidicola and other fungi. It inhibits the growth of eukaryotic cells and certain animal viruses by selectively inhibiting the cellular replication of DNA polymerase II or the viral-induced DNA polymerases. The drug may be useful for controlling excessive cell proliferation in patients with cancer, psoriasis or other dermatitis with little or no adverse effect upon non-multiplying cells.. aphidicolin : A tetracyclic diterpenoid that has an tetradecahydro-8,11a-methanocyclohepta[a]naphthalene skeleton with two hydroxymethyl substituents at positions 4 and 9, two methyl substituents at positions 4 and 11b and two hydroxy substituents at positions 3 and 9. An antibiotic with antiviral and antimitotical properties. Aphidicolin is a reversible inhibitor of eukaryotic nuclear DNA replication.	2	1	0	tetracyclic diterpenoid	antimicrobial agent; antimitotic; antineoplastic agent; antiviral drug; apoptosis inducer; Aspergillus metabolite; DNA synthesis inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; fungal metabolite
amanitins Amanitins: Cyclic peptides extracted from carpophores of various mushroom species. They are potent inhibitors of RNA polymerases in most eukaryotic species, blocking the production of mRNA and protein synthesis. These peptides are important in the study of transcription. Alpha-amanitin is the main toxin from the species Amanitia phalloides, poisonous if ingested by humans or animals.	2	1	0
rhodamine 123 Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.	1.98	1	0	organic cation; xanthene dye	fluorochrome
mitoguazone Mitoguazone: Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase.. mitoguazone : A hydrazone obtained by formal condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine.	2.91	4	0	guanidines; hydrazone	antineoplastic agent; apoptosis inducer; EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor
bis((3-(aminoiminomethyl)phenyl)methylene)carbonimidic dihydrazide trihydrochloride bis((3-(aminoiminomethyl)phenyl)methylene)carbonimidic dihydrazide trihydrochloride: structure given in first source	2.43	2	0
mdl 73811 MDL 73811: structure given in first source; RN given refers to (Z)-isomer	2.4	2	0
robenidine Robenidine: An anticoccidial agent mainly for poultry.	2.43	2	0
s-adenosylmethionine (R)-S-adenosyl-L-methionine : An S-adenosyl-L-methionine that has R-configuration.. S-adenosyl-L-methionine zwitterion : A zwitterionic tautomer of S-adenosyl-L-methionine arising from shift of the proton from the carboxy group to the amino group.. (R)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has R-configuration; major species at pH 7.3.. (S)-S-adenosyl-L-methionine zwitterion : An S-adenosyl-L-methionine zwitterion that has S-configuration; major species at pH 7.3.. S-adenosyl-L-methionine : A sulfonium compound that is the S-adenosyl derivative of L-methionine. It is an intermediate in the metabolic pathway of methionine.	2.71	3	0	organic cation; sulfonium compound	coenzyme; cofactor; human metabolite; micronutrient; Mycoplasma genitalium metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
levoleucovorin Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.	3.4	1	1	5-formyltetrahydrofolic acid	antineoplastic agent; metabolite

Condition	Relationship Strength	Studies	Trials
Carcinogenesis The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.	2.25	1	0
Adenocarcinoma, Basal Cell [description not available]	2.44	2	0
Lymph Node Metastasis [description not available]	2.25	1	0
Cancer of Stomach [description not available]	2.25	1	0
Infections, Helicobacter [description not available]	2.25	1	0
Invasiveness, Neoplasm [description not available]	2.96	4	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.44	2	0
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.25	1	0
Helicobacter Infections Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.	2.25	1	0
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	2.44	2	0
Plasmodium falciparum Malaria [description not available]	2.05	1	0
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.05	1	0
Cholera Infantum [description not available]	3.39	1	1
Blood Diseases [description not available]	4.36	2	2
Benign Neoplasms [description not available]	5.67	5	4
Hematologic Diseases Disorders of the blood and blood forming tissues.	4.36	2	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	5.67	5	4
Disease Exacerbation [description not available]	3.4	1	1
Recrudescence [description not available]	3.4	1	1
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	3.4	1	1
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	3.4	1	1
Cancer of Colon [description not available]	3.4	1	1
Metastase [description not available]	4.66	3	2
Ascites, Gelatinous [description not available]	3.4	1	1
Cancer of Rectum [description not available]	3.4	1	1
Colorectal Cancer [description not available]	3.4	1	1
Colonic Neoplasms Tumors or cancer of the COLON.	3.4	1	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	4.66	3	2
Pseudomyxoma Peritonei A peritoneal adenocarcinoma characterized by build-up of MUCUS in the PERITONEAL CAVITY. Mucus secreting cells may attach to the peritoneal lining and continue to secrete mucus. The majority of cases represent tumor spread from a primary low-grade mucinous neoplasm of the APPENDIX (NCI Thesaurus).	3.4	1	1
Rectal Neoplasms Tumors or cancer of the RECTUM.	3.4	1	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	3.4	1	1
Breast Cancer [description not available]	3.26	6	0
Breast Neoplasms Tumors or cancer of the human BREAST.	3.26	6	0
Malignant Melanoma [description not available]	4.07	3	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	4.07	3	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.02	1	0
Cancer of Lung [description not available]	2.69	3	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.69	3	0
Leukemia L 1210 [description not available]	3.37	7	0
Hormone-Dependent Neoplasms [description not available]	2.4	2	0
Experimental Neoplasms [description not available]	1.98	1	0
Bladder Cancer [description not available]	1.99	1	0
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	1.99	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	1.99	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	1.99	1	0
Cancer of Prostate [description not available]	2.4	2	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.4	2	0
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	2.4	2	0
Hypertrophy General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).	1.99	1	0
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	3.39	1	1
Lassitude [description not available]	3.39	1	1
Emesis [description not available]	3.39	1	1
Anorexia The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.	3.39	1	1
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	3.39	1	1
Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.	3.39	1	1
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	3.39	1	1
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	3.39	1	1
Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).	3.39	1	1

cgp 48664

Description

Cross-References

Synonyms (31)

Research Excerpts

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Research

Studies (51)

Study Types

cgp 48664

Description

Cross-References

Synonyms (31)

Research Excerpts

Pharmacokinetics

Compound-Compound Interactions

Dosage Studied

Research

Studies (51)

Study Types

Related Drugs (27)

Related Conditions (58)